Cohance Lifesciences Ltd

NSE: COHANCE · BSE: 543064 · Pharmaceuticals & Biotechnology · 33 announcements

Share price: ₹455.00
Market cap: ₹17,408 Cr
Revenue (annual): ₹2,269 Cr
Net profit (annual): ₹179.2 Cr
P/E (TTM): 163.9×Sector 47.4×
Promoter holding: 57.49%+0.00% QoQ
FII holding: 6.50%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

5 Aug 2026 17:49 IST NSE

Cohance Lifesciences Q1 FY27 Results: Net Loss of ₹45.2 Cr

Cohance Lifesciences Ltd reported revenue from operations of ₹422.3 Cr (-23.1% YoY) and a net loss of ₹45.2 Cr for Q1 FY27.

Key figure: Net loss ₹45.2 Cr

Open full results → Read the filing ↗

13 May 2026 00:38 IST NSE

Financial Results

Cohance Lifesciences Q4 FY26 Results: Net Profit ₹8.3 Cr, Down 92.9% YoY

Cohance Lifesciences Ltd reported revenue from operations of ₹619.1 Cr (-26.3% YoY) and net profit of ₹8.3 Cr (-92.9% YoY) for Q4 FY26.

Key figure: Net profit ₹8.3 Cr · -92.9% YoY

Open full results → Read the filing ↗

12 May 2026 17:37 IST NSE

Financial Results

Cohance Lifesciences Financial Results

Cohance Lifesciences reported audited FY26 consolidated revenue of ₹2,268.55 Crore. The board also revised authorized personnel for determining materiality effective May 12, 2026.

Read the filing ↗